These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21349771)

  • 1. Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer.
    Motohashi S; Okamoto Y; Yoshino I; Nakayama T
    Clin Immunol; 2011 Aug; 140(2):167-76. PubMed ID: 21349771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy.
    Yamasaki K; Horiguchi S; Kurosaki M; Kunii N; Nagato K; Hanaoka H; Shimizu N; Ueno N; Yamamoto S; Taniguchi M; Motohashi S; Nakayama T; Okamoto Y
    Clin Immunol; 2011 Mar; 138(3):255-65. PubMed ID: 21185787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Invariant NKT cell-based immunotherapy for lung cancer and head and neck cancer].
    Ihara F; Motohashi S
    Nihon Rinsho; 2017 Feb; 75(2):312-316. PubMed ID: 30562870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.
    Schneiders FL; de Bruin RC; Santegoets SJ; Bonneville M; Scotet E; Scheper RJ; Verheul HM; de Gruijl TD; van der Vliet HJ
    Clin Immunol; 2012 Feb; 142(2):194-200. PubMed ID: 22122798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Application of iNKT Cell-mediated Anti-tumor Activity Against Lung Cancer and Head and Neck Cancer.
    Takami M; Ihara F; Motohashi S
    Front Immunol; 2018; 9():2021. PubMed ID: 30245690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invariant natural killer T cell-based immunotherapy for cancer.
    Motohashi S; Nakayama T
    Immunotherapy; 2009 Jan; 1(1):73-82. PubMed ID: 20635975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant activity mediated by iNKT cells.
    Fujii S; Motohashi S; Shimizu K; Nakayama T; Yoshiga Y; Taniguchi M
    Semin Immunol; 2010 Apr; 22(2):97-102. PubMed ID: 19939703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses.
    Hogan AE; Corrigan MA; O'Reilly V; Gaoatswe G; O'Connell J; Doherty DG; Lynch L; O'Shea D
    Clin Immunol; 2011 Sep; 140(3):229-35. PubMed ID: 21684213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma.
    Molling JW; Langius JA; Langendijk JA; Leemans CR; Bontkes HJ; van der Vliet HJ; von Blomberg BM; Scheper RJ; van den Eertwegh AJ
    J Clin Oncol; 2007 Mar; 25(7):862-8. PubMed ID: 17327607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide.
    Hogan AE; O'Reilly V; Dunne MR; Dere RT; Zeng SG; O'Brien C; Amu S; Fallon PG; Exley MA; O'Farrelly C; Zhu X; Doherty DG
    Clin Immunol; 2011 Aug; 140(2):196-207. PubMed ID: 21493160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases.
    Molling JW; Moreno M; de Groot J; van der Vliet HJ; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
    Immunol Lett; 2008 Jun; 118(1):36-43. PubMed ID: 18405982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokine-dependent modification of IL-12p70 and IL-23 balance in dendritic cells by ligand activation of Valpha24 invariant NKT cells.
    Uemura Y; Liu TY; Narita Y; Suzuki M; Nakatsuka R; Araki T; Matsumoto M; Iwai LK; Hirosawa N; Matsuoka Y; Murakami M; Kimura T; Hase M; Kohno H; Sasaki Y; Ichihara Y; Ishihara O; Kikuchi H; Sakamoto Y; Jiao SC; Senju S; Sonoda Y
    J Immunol; 2009 Jul; 183(1):201-8. PubMed ID: 19542431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Invariant natural killer T cells and immunotherapy of cancer.
    Molling JW; Moreno M; van der Vliet HJ; van den Eertwegh AJ; Scheper RJ; von Blomberg BM; Bontkes HJ
    Clin Immunol; 2008 Nov; 129(2):182-94. PubMed ID: 18783990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells.
    Moreno M; Molling JW; von Mensdorff-Pouilly S; Verheijen RH; von Blomberg BM; van den Eertwegh AJ; Scheper RJ; Bontkes HJ
    Clin Immunol; 2008 Oct; 129(1):145-54. PubMed ID: 18707922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of iNKT cells in the immunopathology of systemic lupus erythematosus.
    Gabriel L; Morley BJ; Rogers NJ
    Ann N Y Acad Sci; 2009 Sep; 1173():435-41. PubMed ID: 19758183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Translational research of NKT cell-based immunotherapy].
    Motohashi S; Nakayama T
    Nihon Yakurigaku Zasshi; 2010 Dec; 136(6):344-7. PubMed ID: 21139286
    [No Abstract]   [Full Text] [Related]  

  • 18. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation.
    Cullen R; Germanov E; Shimaoka T; Johnston B
    J Immunol; 2009 Nov; 183(9):5807-15. PubMed ID: 19812206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of invariant NK T lymphocytes in immune responses to CpG oligodeoxynucleotides.
    Paget C; Bialecki E; Fontaine J; Vendeville C; Mallevaey T; Faveeuw C; Trottein F
    J Immunol; 2009 Feb; 182(4):1846-53. PubMed ID: 19201836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of activated invariant natural killer T cells in the tumor microenvironment after α-galactosylceramide-pulsed antigen presenting cells.
    Nagato K; Motohashi S; Ishibashi F; Okita K; Yamasaki K; Moriya Y; Hoshino H; Yoshida S; Hanaoka H; Fujii S; Taniguchi M; Yoshino I; Nakayama T
    J Clin Immunol; 2012 Oct; 32(5):1071-81. PubMed ID: 22534863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.